Article Highlight | 6-Mar-2024

Outcomes of patients undergoing elective pancreatic surgery during COVID-19 pandemic

Xia & He Publishing Inc.

Background and objectives

The coronavirus disease 2019 (COVID-19) pandemic continues to affect global health, and the emergence of new variants has added a layer of uncertainty to medical practice. Although elective surgeries are recommended to be postponed for at least 7 weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to be considered safe, the safety and optimal timing for pancreatic surgery after this infection remains unknown.

 

Methods

Conducted in four high-volume pancreas centers in China, this prospective, multicenter clinical trial aimed to provide a realistic representation of the key perioperative parameters for pancreatic surgery after SARS-CoV-2 infection. The primary outcome was 30-day perioperative survival, and the secondary outcomes included major complications, pulmonary complications, and surgical complications.

 

Results

Our results revealed that elective pancreatic surgery within 4 weeks of SARS-CoV-2 infection may be correlated with a prolonged hospital stay. Specifically, patients who underwent surgery within 0–2 weeks (24.7 days average) or 3–4 weeks (21.8 days average) after infection had obviously longer hospital stays compared to those without prior infection (15.5 days average) or those who underwent surgery more than 4 weeks after infection. However, there was no apparent increase in the total postoperative complications classified as Clavien-Dindo grade ≥ 3, even among patients who underwent surgery within 2 weeks after SARS-CoV-2 infection.

 

Conclusions

No significant increase in major complications is observed among patients undergoing pancreatic surgery following a diagnosis of SARS-CoV-2. However, it would be safer to perform pancreatic surgery at least 4 weeks after SARS-CoV-2 infection.

 

https://www.xiahepublishing.com/2835-3315/CSP-2023-00001S

 

The study was recently published in the Cancer Screening and Prevention.

Cancer Screening and Prevention (CSP) publishes high-quality research and review articles related to cancer screening and prevention. It aims to provide a platform for studies that develop innovative and creative strategies and precise models for screening, early detection, and prevention of various cancers. Studies on the integration of precision cancer prevention multiomics where cancer screening, early detection and prevention regimens can precisely reflect the risk of cancer from dissected genomic and environmental parameters are particularly welcome.

 

Follow us on X: https://twitter.com/xiahepublishing

Follow us on LinkedIn: https://www.linkedin.com/company/xia&he-publishing-inc/

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.